Moderna (NASDAQ: MRNA) Posts Q1 Loss as Revenue Declines 29.8%

Moderna shares declined 1.24% to $45.37 on Friday following the release of Q1 2026 earnings that reveal a company in acute distress: revenue plummeted 29.8% year-over-year, while the company posted substantial losses on a negative gross margin basis. The biotech firm faces a dramatic reversal from its pandemic-era profitability.

Q1 2026 At a Glance

• Gross margin: -105.76%, indicating cost of goods exceed revenue
• Operating margin: -126.4%, reflecting massive operating losses
• Net margin: -145.16%, signaling compounded losses
• Revenue decline: -29.8% year-over-year
• Forward P/E: Not meaningful (negative)

What Drove the Results

Moderna's negative gross margin of -105.76% is alarming and indicates that the company is spending $1.06 to generate $1 of revenue—a structural problem rather than a temporary loss. This typically reflects a combination of lower vaccine demand (as COVID-19 endemic rates stabilize and vaccination cycles mature) and fixed manufacturing costs that cannot scale down proportionally with volume declines.

The 29.8% revenue collapse compounds the problem. With fewer vaccine doses sold at lower pricing (due to competition and inventory correction in healthcare systems worldwide), Moderna cannot absorb its manufacturing footprint and R&D costs. The result: operating losses of 126.4%—meaning the company burns cash even on an operational basis before financing.

Investor Takeaway

Moderna is in survival mode. The negative gross margin signals that the company's vaccine manufacturing economics have inverted—a critical red flag. The 29.8% revenue decline reflects both the predictable normalization from pandemic peaks and aggressive competitive pricing in respiratory vaccines (RSV, flu, COVID boosters). Until Moderna demonstrates either (a) meaningful revenue stabilization, (b) gross margin recovery to breakeven or positive territory, or (c) success in new programs like rare disease and oncology therapeutics, the stock remains a value trap. Investors should await clarity on cost structure reductions and pipeline progress before considering re-entry.